Soleno Therapeutics Inc (SLNO)

Currency in USD
63.7550
-1.8050(-2.75%)
Closed·
62.4800-1.2750(-2.00%)
·
SLNO Scorecard
Full Analysis
Significant return over the last week
SLNO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
63.580066.0950
52 wk Range
41.500090.3199
Key Statistics
Prev. Close
65.56
Open
65
Day's Range
63.58-66.095
52 wk Range
41.5-90.3199
Volume
1.04M
Average Volume (3m)
1.8M
1-Year Change
25.5%
Book Value / Share
4.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLNO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
119.0000
Upside
+86.65%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

Soleno Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Soleno Therapeutics Inc Company Profile

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Soleno Therapeutics Inc SWOT Analysis


VYKAT XR Breakthrough
Explore Soleno's FDA-approved treatment for Prader-Willi Syndrome, addressing hyperphagia in a 12,000-patient U.S. market with potential global expansion
Market Dynamics
Delve into VYKAT XR's commercial launch, pricing strategy, and early adoption metrics, with analysts projecting peak sales of up to $2.8 billion worldwide
Financial Outlook
Discover Soleno's strong cash position of $290 million and analyst expectations of profitability, with EPS forecasts of $6.65 for FY2025
Analyst Consensus
Learn about the "Strong Buy" recommendation and median price target suggesting 37% upside, with targets ranging from $20 to $145 per share
Read full SWOT analysis

Soleno Therapeutics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of -$0.09 beat forecast of -$0.64; revenue of $32.7M exceeded expectations by 113.03%
  • VICAT XR launch successful; company exploring European market expansion for PWS treatment
  • Pro forma cash balance over $500M; projecting annual cash operating expenses of $120-130M
  • Stock dipped 0.54% post-earnings despite strong results; analyst targets suggest potential upside
  • No new safety signals for VICAT XR; company actively seeking strategic partnerships for European entry
Last Updated: 07/08/2025, 08:36
Read Full Transcript

Compare SLNO to Peers and Sector

Metrics to compare
SLNO
Peers
Sector
Relationship
P/E Ratio
−18.7x−3.8x−0.7x
PEG Ratio
0.220.130.00
Price/Book
14.1x0.9x2.6x
Price / LTM Sales
103.8x13.0x3.4x
Upside (Analyst Target)
88.2%203.8%38.0%
Fair Value Upside
Unlock8.2%5.3%Unlock

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 119.0000
(+86.65% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.09 / -0.64
Revenue / Forecast
32.70M / 15.35M
EPS Revisions
Last 90 days

SLNO Income Statement

People Also Watch

206.21
ALAB
-8.53%
39.240
SMR
-3.37%
61.555
QURE
-3.29%
292.96
ORCL
-1.35%

FAQ

What Stock Exchange Does Soleno Therapeutics Trade On?

Soleno Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Soleno Therapeutics?

The stock symbol for Soleno Therapeutics is "SLNO."

What Is the Soleno Therapeutics Market Cap?

As of today, Soleno Therapeutics market cap is 3.39B.

What Is Soleno Therapeutics's Earnings Per Share (TTM)?

The Soleno Therapeutics EPS (TTM) is -3.97.

When Is the Next Soleno Therapeutics Earnings Date?

Soleno Therapeutics will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is SLNO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Soleno Therapeutics Stock Split?

Soleno Therapeutics has split 2 times.

How Many Employees Does Soleno Therapeutics Have?

Soleno Therapeutics has 133 employees.

What is the current trading status of Soleno Therapeutics (SLNO)?

As of 11 Oct 2025, Soleno Therapeutics (SLNO) is trading at a price of 63.7550, with a previous close of 65.56. The stock has fluctuated within a day range of 63.5800 to 66.0950, while its 52-week range spans from 41.5000 to 90.3199.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.